STLN
STARLING ONCOLOGY INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
STARLING ONCOLOGY INC (STLN) is held as common stock by 3 tracked hedge-fund managers, with a combined reported value of ~$12.80M; the largest are Renaissance Technologies, Ken Griffin, Izzy Englander. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 2 added, 1 trimmed. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · LowThis quarter · Quiet
Common-stock holders31 also report options
Congress trades0
Price$6.51vs quarter-end+19.89%
Sectors0
This quarter's moves
Top holderNew0
Added2
Trimmed / sold1
Renaissance TechnologiesCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
| Investor | Value | % of portfolio | Action |
|---|
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $4.18M— of portfolio769,2002026 Q2
Value $404.0K— of portfolio74,4002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $4.18M | — | — |
| Ken GriffinPUT | $404.0K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.